Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
1 hedge funds and large institutions have $4K invested in Genocea Biosciences, Inc. in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
80% less funds holding
Funds holding: 5 → 1 (-4)
96% less capital invested
Capital invested by funds: $92K → $4K (-$88K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$86K |
GNCA Hedge Fund Activity: Q3 2022 in Review
1 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2022, worth a combined $4K — down 96% from $92K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GNCA and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $86K sold.
- 1 institutional investor held Genocea Biosciences, Inc. (GNCA) as of Q3 2022, down from 5 in Q2 2022.
- Funds reported $4K of Genocea Biosciences, Inc. stock for Q3 2022, down 96% quarter-over-quarter.
- 0 funds opened new Genocea Biosciences, Inc. positions in Q3 2022 and 4 closed out, a net change of -4 holders.
- The largest Genocea Biosciences, Inc. seller in Q3 2022 was Avoro Capital Advisors, an estimated $86K sold.
Based on aggregated 13F filings for Q3 2022.